Shares of Lupin Ltd are trading flat on 30th December after touching a day’s high of Rs 2,098.80, despite the company saying it has inked an exclusive licensing, supply, and distribution agreement for a GLP-1 drug.

Lupin has entered into an exclusive licensing, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide. Under this deal, Lupin will have exclusive rights to commercialise and distribute the drug in India.

Bofanglutide is a GLP-1 injectable given once every two weeks. It is used for the treatment of Type 2 diabetes and weight management, offering a longer dosing gap compared to existing therapies.

According to Lupin, the drug is potentially first-in-class globally. Clinical data suggest that its weight-loss effectiveness is comparable to, or better than, that of currently available GLP-1 drugs.

A key advantage of Bofanglutide is its less frequent dosing schedule. Unlike most GLP-1 treatments that require weekly injections, this drug needs to be taken only once every two weeks.

Overall, the agreement strengthens Lupin’s diabetes treatment portfolio and helps fast-track its entry into the growing obesity treatment segment.

At 10:35 AM, shares of Lupin were trading 0.15% higher at Rs 2,085.30 on NSE.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!